Association between the FMR1 CGG repeat lengths and the severity of idiopathic primary ovarian insufficiency: a meta analysis

Figures & data

Figure 1. Flow diagram of screening for relevant articles in meta-analysis of data on the CGG repeat length and idiopathic POI.

Table 1. Characteristics of studies included in the Meta-Analysis between the CGG repeat length in the FMR1 gene and idiopathic POI.

						Sample size
Author	Year	Study type	Country	Ethnicity	Method	DOR	POI	Controls
Bretherick et al.	2005	A prospective cohort study	Canada	Caucasian	PCR + ABI 3100 analyzer	--	53	182
Bodega et al.	2006	Case-control study	Italy	Italian	PCR + ABI 3100 analyzer	--	190	200
Streuli et al	2009	Retrospective, case-control study	Switzerland	NA	PCR + Southern blot analysis	27	--	32
Chatterjee et al.	2009	Case-control study	India	South Asian	PCR + Southern blot analysis	--	78	70
Ishizuka et al.	2011	Retrospective, controlled cohort study	Japan	East Asian	PCR + ABI 3100 analyzer	--	128	98
Karimov et al	2011	Case-control study	USA	NA	PCR + Southern blot analysis	535	--	521
Pastore et al.	2012	Prospective multicenter cohort study	USA	Caucasian	PCR + Southern blot analysis	62	--	161
Lin et al	2013	Case-control study	China	Chinese	PCR + ABI 3730 analyzer	--	85	80
De Geyter et al.	2013	A prospective cohort study	Switzerland	Caucasian	PCR + ABI 3130 analyzer	--	48	199
Murray et al.	2013	A prospective cohort study	UK	European	PCR + ABI 3730 analyzer	--	254	1915
Barasoain M	2013	Case-control study	Basque	Basque	PCR + ABI 3130 analyzer	34	7a	32
Ye et al.	2014	Case-control study	China	Chinese	PCR + ABI 3130 analyzer	--	117	82
Guo et al.	2014	A large cohort study	China	Chinese	PCR + ABI 3130 analyzer	--	379	402
Voorhuis et al.	2014	A large Case-control study	Netherlands	European	PCR + Southern blot analysis and PCR + ABI 3130 analyzer		379	3370
Lisa M. Pastore et al.	2016	Case-control study	USA	Caucasian	PCR + ABI 3700 analyzer	129	--	803
Rezvaneh Asadi et al.	2018	Case-control study	Iran	Iranian	PCR + ABI 3730 analyzer	--	30	30
Luc ía Daniela Espeche et al.	2017	Case-control study	Argentina	Latin American populations	PCR + Southern blot analysis	--	133	84
Ali Eslami et al.	2016	Case-control study	Iran	Iranian	PCR + ABI 3730 analyzer	188	173	200

Notes: NA: data not available; --: data didn’t mention in the studies; a: small sample size didn’t include in meta-analysis.

Table 2. The distributions of intermediate and premutation alleles of the included studies in women with POI and DOR.

	Cases				Controls
Articles	Intermediate (45–54)	Premutation (55–200)	Total	Intermediate (45–54)	Premutation (55–200)	Total
(POI)
Bretherick KL, 2005	0 (0.0%)	2 (3.8%)	53	3 (1.6%)	1 (0.5%)	182
Bodega B, 2006	4 (2.1%)	19 (10.0%)	190	2 (1.0%)	0 (0.0%)	200
Chatterjee S, 2009	1 (1.3%)	1 (1.3%)	78	1 (1.4%)	1 (1.4%)	70
Ishizuka B, 2011	1 (0.8%)	2 (1.6%)	128	1 (1.0%)	0 (0.0%)	98
Lin L, 2013	1 (1.2%)	1 (1.2%)	85	1 (1.3%)	1 (1.3%)	80
De Geyter C, 2013	0 (0.0%)	1 (2.1%)	48	4 (2.0%)	1 (0.5%)	199
Murray A, 2013	7 (2.8%)	5 (2.0%)	254	53 (2.8%)	7 (0.4%)	1915
Ye Y, 2014	0 (0.0%)	1 (0.9%)	117	0 (0.0%)	0 (0.0%)	82
Guo T, 2014	11 (2.9%)	2 (0.5%)	379	7 (1.7%)	0 (0.0%)	402
Voorhuis, 2014	10 (2.6%)	4 (1.1%)	379	123 (3.6%)	2 (0.006%)	3370
Ali Eslami, 2016	26 (15.0%)	20 (11.6%)	173	40 (20.0%)	0 (0.0%)	200
Rezvaneh Asadi, 2018	4 (13.3%)	1 (3.3%)	30	1 (3.3%)	0 (0%)	30
Luc ía Daniela Espeche, 2017	1 (0.8%)	2 (1.5%)	133	1 (1.2%)	1 (1.2%)	84
Total	66 (3.2%)	61 (2.0%)	2047	236 (3.4%)	14 (0.2%)	6912
(DOR)
Streuli I, 2009	1 (3.7%)	2 (7.4%)	27	1 (3.1%)	0 (0.0%)	32
Karimov CB, 2011	17 (3.2%)	7 (1.3%)	535	7 (1.3%)	1 (0.2%)	521
Pastore LM, 2012	1 (1.6%)	1 (1.6%)	62	3 (1.9%)	1 (0.6%)	161
Barasoain M, 2013	1 (2.9%)	2 (5.9%)	34	0 (0.0%)	0 (0.0%)	32
Pastore LM, 2016	3 (2.3%)	1 (0.8%)	129	13 (1.6%)	1 (0.1%)	803
Ali Eslami, 2016	25 (13.3%)	30 (15.95%)	188	40 (20.0%)	0 (0.0%)	200
Total	48 (4.9%)	43 (4.4%)	975	64 (3.7%)	3 (0.2%)	1749

Figure 2. The prevalence of premutation and intermediate alleles in POI.

Figure 3. The prevalence of premutation and intermediate alleles in DOR.